SHORT MINI FUTURE WARRANT - BRISTOL-MYERS SQUIBB | Real-time BOERSE MUENCHEN 09:55:08 17/06/2024 pm IST | ||
| 1.576 EUR | +3.28% |
|
| Current month | -1.36% | ||
| 1 month | +25.08% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about BRISTOL-MYERS SQUIBB COMPANY
More news
| Date | Price | Change |
|---|---|---|
| 17/24/17 | 1.576 | +3.28% |
| 14/24/14 | 1.526 | +0.66% |
| 13/24/13 | 1.516 | +8.75% |
| 12/24/12 | 1.394 | -0.85% |
| 11/24/11 | 1.406 | -2.36% |
Real-time BOERSE MUENCHEN
Last update June 17, 2024 at 09:55 pm IST
More quotesStatic data
| Product type | Knock-Out mit Stop Loss |
|---|---|
| Buy / Sell | PUT |
| Underlying | BRISTOL-MYERS SQUIBB COMPANY |
| Issuer | Goldman Sachs |
| WKN | GQ7P7X |
| ISIN | DE000GQ7P7X0 |
| Date issued | 18/10/2023 |
| Strike | 57.82 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 0.13 € |
| Emission volume | N/A |
| Settlement | Barausgleich |
| Currency | EUR |
Technical Indicators
| Highest since issue | 1.645 € |
|---|---|
| Lowest since issue | 0.171 € |
| Spread | 0.01 € |
| Spread % | 0.63% |
Company Profile
Bristol-Myers Squibb Company est spécialisé dans le développement, la fabrication et la commercialisation de produits pharmaceutiques. Les produits sont destinés au traitement des cancers, des maladies cardio-vasculaires, de l'hépatite, des maladies immunitaires et des désordres psychiatriques.
The United States account for 70.1% of net sales.
Sector
-
Ratings for Bristol-Myers Squibb Company
Trading Rating
Investor Rating
ESG Refinitiv
B
Consensus: Bristol-Myers Squibb Company
Sell
Buy
Mean consensus
HOLD
Number of Analysts
26
Last Close Price
41.2
USD
Average target price
53.19
USD
Spread / Average Target
+29.11%
- Stock Market
- Certificates
- Certificat
